| Name: | Abemaciclib Mesylate |
| Catalogue No. | VL4990001 |
| CAS No. | 1231930-82-7 |
| Molecular Formula | C₂₈H₃₆F₂N₈O₃S |
| Molecular Weight | 602.7 |
| Status | Under Development |
| IUPAC Name | N-[5-[(4-Ethyl-1-piperazinyl)methyl]-2-pyridinyl]-5-fluoro-4-[4-fluoro-2-methyl-1-(1-methylethyl)-1H-benzimidazol-6-yl]-2-pyrimidinamine Methanesulfonate |
| Description | Abemaciclib Mesylate (CAS No: 1231930-82-7) belonging to the class of Aminopyridines is an inhibitor of cyclin-dependent kinases 4 and 6 that is used in the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. |
| References | Kim, Esther S. “Abemaciclib: First Global Approval.” Drugs, vol. 77, no. 18, Nov. 2017, pp. 2063–70, https://doi.org/10.1007/s40265-017-0840-z. |